These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37201428)

  • 1. Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives.
    Hu J; Zhang D; Tian K; Ren C; Li H; Lin C; Huang X; Liu J; Mao W; Zhang J
    Eur J Med Chem; 2023 Aug; 256():115475. PubMed ID: 37201428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling Parkinson's disease in LRRK2 mice: focus on synaptic dysfunction and the autophagy-lysosomal pathway.
    Albanese F; Domenicale C; Volta M; Morari M
    Biochem Soc Trans; 2022 Feb; 50(1):621-632. PubMed ID: 35225340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of LRRK2 in Intracellular Organelle Dynamics.
    Boecker CA
    J Mol Biol; 2023 Jun; 435(12):167998. PubMed ID: 36764357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.
    Chang EES; Ho PW; Liu HF; Pang SY; Leung CT; Malki Y; Choi ZY; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Feb; 11(1):10. PubMed ID: 35152914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
    Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
    Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.
    Tang X; Xing S; Ma M; Xu Z; Guan Q; Chen Y; Feng F; Liu W; Chen T; Chen Y; Sun H
    J Med Chem; 2023 Feb; 66(4):2282-2307. PubMed ID: 36758171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 and the Endolysosomal System in Parkinson's Disease.
    Erb ML; Moore DJ
    J Parkinsons Dis; 2020; 10(4):1271-1291. PubMed ID: 33044192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 along the Golgi and lysosome connection: a jamming situation.
    Piccoli G; Volta M
    Biochem Soc Trans; 2021 Nov; 49(5):2063-2072. PubMed ID: 34495322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LRRK2-macroautophagy axis and its relevance to Parkinson's disease.
    Manzoni C
    Biochem Soc Trans; 2017 Feb; 45(1):155-162. PubMed ID: 28202669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
    Wojewska DN; Kortholt A
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease.
    Cookson MR
    Biochem Soc Trans; 2016 Dec; 44(6):1603-1610. PubMed ID: 27913668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.
    Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL
    Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-Molecule Inhibitors of LRRK2.
    Hatcher JM; Choi HG; Alessi DR; Gray NS
    Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
    Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.